stockrow
Saturday 7 November 2026
Export ANIX’s income statement to Excel — free account
ANIXA BIOSCIENCES INC
ANIX Healthcare Biotechnology
ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00.
- EPS
- −14.3%
- Free cash flow
- −17.1%
Quarter to July 2026, against a year earlier
3.16
0.13
+4.29%
Follow ANIX
Alert me
ANIXA BIOSCIENCES INC (ANIX) P/E ratio
ANIXA BIOSCIENCES INC has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Apr 2023 | 0.0× | — |
| Oct 2021 | 0.0× | — |
| Jan 2021 | 0.0× | — |
| Apr 2019 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NBP NovaBridge Biosciences compare | n/m |
| VYGR Voyager Therapeutics, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| ANIX ANIXA BIOSCIENCES INC | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)